Xenon Pharmaceuticals Inc. is a biopharmaceutical firm discovering and developing a pipeline of differentiated therapeutics for orphan indications. The company has a market cap of $97.37 million. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). It currently has negative earnings. Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes.

The post Xenon Pharmaceuticals Inc (XENE) Earnings Per Share Expected to Increase appeared first on Octafinance.